Bioadhesive chitosan gel for controlling bleeding and for promoting healing with scar reduction without obscuring or interfering with access to a surgical field
An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt.
1. An aqueous gel comprising:
water in an amount greater than about 88% (w/w);
chitosan in an amount of about 3% (w/w);
an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w), a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), or an inorganic phosphoric, triphosphoric, or polyphosphoric acid in an amount up to about 3% (w/w), and wherein lactic acid, a monofunctional organic acid, is included in an amount of about 2% (w/w);
a rheology modifying agent including hydroxyl propyl methyl cellulose in an amount of about 0.5% (w/w), polyethylene oxide in an amount of about 0.2% (w/w), poloxamer in an amount of about 0.2% (w/w), and polypropylene glycol in an amount of about 0.1% (w/w);
an antioxidant stabilizer in an amount of about 0.1% to about 2.5% (w/w), wherein said antioxidant stabilizer is selected from the group consisting of methylparaben, tannic acid, trolox, quercetin, catechin, glutathione, ferulic acid, carotenoid, proanthocyanidin, and ascorbic acid, and including methylparaben in an amount of about 0.2%;
an alcohol in an amount of about 0.2% to about 10% (w/w), and including ethanol in an amount of about 5% (w/w); and
a multi-valent salt in an amount of about 0.1% to about 0.5% (w/w), and including CaCl 2 in an amount of about 0.3% (w/w).
2. The aqueous gel of claim 1 , wherein the aqueous gel is at least one of clear and transparent.
3. The aqueous gel of claim 1 , wherein the aqueous gel is stable for a period up to three years at about 23° C.
4. The aqueous gel of claim 1 , further comprising at least one of a plasticizer in an amount up to about 5% (w/w) or an anti-microbial agent.
5. The aqueous gel of claim 1 , wherein the aqueous gel is bioabsorbable and the chitosan has a percent degree of deacetylation between 20% and 40%.
6. The aqueous gel of claim 1 , wherein the aqueous gel is removable and the chitosan has a percent degree of deacetylation greater than about 78%.
7. An aqueous gel comprising:
water in an amount greater than about 83.5% (w/w);
chitosan in an amount of about 5.7% (w/w);
an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w), a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), or an inorganic phosphoric, triphosphoric, or polyphosphoric acid in an amount up to about 3% (w/w), and wherein lactic acid, a monofunctional organic acid, is included in an amount of about 3.5% (w/w);
a rheology modifying agent including hydroxyl propyl methyl cellulose in an amount of about 0.5% (w/w), polyethylene oxide in an amount of about 0.2% (w/w), poloxamer in an amount of about 0.2% (w/w), and polypropylene glycol in an amount of about 0.1% (w/w);
ascorbic acid in an amount of about 1% (w/w);
an alcohol in an amount of about 0.2% to about 10% (w/w), and including ethanol in an amount of about 5% (w/w); and
a multi-valent salt in an amount of about 0.1% to about 0.5% (w/w), and including CaCl 2 in an amount of about 0.3% (w/w).
8. The aqueous gel of claim 7 , wherein the aqueous gel is at least one of clear and transparent.
9. The aqueous gel of claim 7 , wherein the aqueous gel is stable for a period up to three years at about 23° C.
10. The aqueous gel of claim 7 , further comprising at least one of a plasticizer in an amount up to about 5% (w/w) or an anti-microbial agent.
11. The aqueous gel of claim 7 , wherein the aqueous gel is bioabsorbable and the chitosan has a percent degree of deacetylation between 20% and 40%.
12. The aqueous gel of claim 7 , wherein the aqueous gel is removable and the chitosan has a percent degree of deacetylation greater than about 78%.
13. An aqueous gel comprising:
water in an amount greater than about 80% (w/w);
chitosan in an amount of about 2% to about 12% (w/w);
an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w), a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), or an inorganic phosphoric, triphosphoric, or polyphosphoric acid in an amount up to about 3% (w/w);
a rheology modifying agent in an amount of about 0.5% to about 5% (w/w);
an antioxidant stabilizer in an amount of about 0.1% to about 2.5% (w/w), wherein said antioxidant stabilizer is selected from the group consisting of methylparaben, tannic acid, trolox, quercetin, catechin, glutathione, ferulic acid, carotenoid, proanthocyanidin, and ascorbic acid;
an alcohol in an amount of about 0.2% to about 10% (w/w);
a multi-valent salt in an amount of about 0.1% to about 0.5% (w/w); and
an anti-microbial agent, wherein the antimicrobial agent is selected from the group consisting of silver, chitosan derivatives that are polycationic between pH 6.8-7.8, chlorhexidine gluconate, iodine and polyhexamethyl biguanide.
14. The aqueous gel of claim 13 , wherein the aqueous gel is at least one of clear and transparent.
15. The aqueous gel of claim 13 , wherein the aqueous gel is stable for a period up to three years at about 23° C.
16. The aqueous gel of claim 13 , further comprising at least one of a plasticizer in an amount up to about 5% (w/w) or an anti-microbial agent.
17. The aqueous gel of claim 13 , wherein the aqueous gel is bioabsorbable and the chitosan has a percent degree of deacetylation between 20% and 40%.
18. The aqueous gel of claim 13 , wherein the aqueous gel is removable and the chitosan has a percent degree of deacetylation greater than about 78%.
19. A surgical method comprising applying to an injury an aqueous gel comprising:
water in an amount greater than about 88% (w/w);
chitosan in an amount of about 3% (w/w);
an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w), a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), or an inorganic phosphoric, triphosphoric or polyphosphoric acid in an amount up to about 3% (w/w), and wherein lactic acid, a monofunctional organic acid, is included in an amount of about 2% (w/w);
a rheology modifying agent including hydroxyl propyl methyl cellulose in an amount of about 0.5% (w/w), polyethylene oxide in an amount of about 0.2% (w/w), poloxamer in an amount of about 0.2% (w/w, and polypropylene glycol in an amount of about 0.1% (w/w);
an antioxidant stabilizer in an amount of about 0.1% to about 2.5% (w/w), wherein said antioxidant stabilizer is selected from the group consisting of methylparaben, tannic acid, trolox, quercetin, catechin, glutathione, ferulic acid, carotenoid, proanthocyanidin, and ascorbic acid, and including methylparaben in an amount of about 0.2%;
an alcohol in an amount of about 0.2% to about 10% (w/w), and including ethanol in an amount of about 5% (w/w); and
a multi-valent salt in an amount of about 0.1% to about 0.5% (w/w), and including CaCl 2 in an amount of about 0.3% (w/w), to control bleeding or facilitate hemostasis during or after one or more of sinus surgery, ear nose and throat procedures, oral and maxillofacial surgery, orthopedic surgery, urological surgery, reconstructive surgery, cosmetic surgery, vascular surgery, transplant surgery, neurological surgery, oncological resection surgery involving the biopsy and removal of tumors, gynecological surgery, and general topical bleeding.
20. The method of claim 19 , wherein the chitosan interacts with components of blood in the injury to control bleeding and facilitate hemostasis.
21. The method of claim 19 , further comprising allowing bioabsorption of the aqueous gel, wherein the chitosan has a percent degree of deacetylation between 20% and 40%.
22. The method of claim 19 , further comprising removing the aqueous gel from the injury, wherein the chitosan has a percent degree of deacetylation greater than about 78%.
23. A surgical method comprising applying to an injury an aqueous gel comprising
water in an amount greater than about 83.5% (w/w);
chitosan in an amount of about 5.7% (w/w);
an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w), a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), or an inorganic phosphoric, triphosphoric, or polyphosphoric acid in an amount up to about 3% (w/w), and wherein lactic acid, a monofunctional organic acid, is included in an amount of about 3.5% (w/w);
a rheology modifying agent including hydroxyl propyl methyl cellulose in an amount of about 0.5% (w/w), polyethylene oxide in an amount of about 0.2% (w/w), poloxamer in an amount of about 0.2% (w/w), and polypropylene glycol in an amount of about 0.1% (w/w);
ascorbic acid in an amount of about 1% (w/w);
an alcohol in an amount of about 0.2% to about 10% (w/w), and including ethanol in an amount of about 5% (w/w); and
a multi-valent salt in an amount of about 0.1% to about 0.5% (w/w), and including CaCl 2 in an amount of about 0.3% (w/w), to control bleeding or facilitate hemostasis during or after one or more of sinus surgery, ear nose and throat procedures, oral and maxillofacial surgery, orthopedic surgery, urological surgery, reconstructive surgery, cosmetic surgery, vascular surgery, transplant surgery, neurological surgery, oncological resection surgery involving the biopsy and removal of tumors, gynecological surgery, and general topical bleeding.
24. The method of claim 23 , wherein the chitosan interacts with components of blood in the injury to control bleeding and facilitate hemostasis.
25. The method of claim 23 , further comprising allowing bioabsorption of the aqueous gel, wherein the chitosan has a percent degree of deacetylation between 20% and 40%.
26. The method of claim 23 , further comprising removing the aqueous gel from the injury, wherein the chitosan has a percent degree of deacetylation greater than about 78%.
27. A surgical method comprising applying to an injury an aqueous gel comprising:
water in an amount greater than about 80% (w/w);
chitosan in an amount of about 2% to about 12% (w/w),
an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w) a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), or an inorganic phosphoric, triphosphoric, or polyphosphoric acid in an amount up to about 3% (w/w);
a rheology modifying agent in an amount of about 0.5% to about 5% (w/w);
an antioxidant stabilizer in an amount of about 0.1% to about 2.5% (w/w), wherein said antioxidant stabilizer is selected from the group consisting of methylparaben, tannic acid, trolox, quercetin, catechin, glutathione, ferulic acid, carotenoid, proanthocyanidin, and ascorbic acid;
an alcohol in an amount of about 0.2% to about 10% (w/w);
a multi-valent salt in an amount of about 0.1% to about 0.5% (w/w); and
an anti-microbial agent, wherein the antimicrobial agent is selected from the group consisting of silver, chitosan derivatives that are polycationic between pH 6.8-7.8, chlorhexidine gluconate, iodine and polyhexamethyl biguanide, to control bleeding or facilitate hemostasis during or after one or more of sinus surgery, ear nose and throat procedures, oral and maxillofacial surgery, orthopedic surgery, urological surgery, reconstructive surgery, cosmetic surgery, vascular surgery, transplant surgery, neurological surgery, oncological resection surgery involving the biopsy and removal of tumors, gynecological surgery, and general topical bleeding.
28. The method of claim 27 , wherein the chitosan interacts with components of blood in the injury to control bleeding and facilitate hemostasis.
29. The method of claim 27 , further comprising allowing bioabsorption of the aqueous gel, wherein the chitosan has a percent degree of deacetylation between 20% and 40%.
30. The method of claim 27 , further comprising removing the aqueous gel from the injury, wherein the chitosan has a percent degree of deacetylation greater than about 78%.